Argenx enters into agreement to acquire priority review voucher

November 23, 2020 breda, the netherlands / ghent, belgium – argenx (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the company has agreed to acquire a u.s. food and drug administration (fda) priority review voucher (prv) from bayer healthcare pharmaceuticals, inc for $98 million. a prv entitles the holder to fda priority review of a single new drug application or biologics license application (bla), which reduces the target review time and may potentially lead to an expedited approval.
ARGX Ratings Summary
ARGX Quant Ranking